GlassScriptPhysician profile
Dorane Thornton
NPI 1831505338
$4,012.82
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,608 · 2022: $1,613 · 2023: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $485.39 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $439.07 | 2021-2022 | |
| Mylan Specialty L.P. | $434.28 | 2021-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $375.78 | 2021-2023 | Cuvitru, Glassia |
| Grifols USA, LLC | $325.68 | 2021-2023 | Xembify |
| Csl Behring | $268.21 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $250.69 | 2021-2023 | Dupixent |
| Genzyme Corporation | $243.80 | 2021-2023 | |
| Genentech USA, INC. | $207.64 | 2021-2023 | Xolair |
| Pfizer INC. | $181.33 | 2021-2023 | |
| Amgen INC. | $166.97 | 2021-2023 | Tezspire |
| Leo Pharma INC. | $161.95 | 2022-2023 | Adbry |
| Pharming Healthcare, INC. | $97.61 | 2022-2023 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $95.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $74.34 | 2021-2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $72.08 | 2021 | |
| Biocryst US Sales Co., LLC | $44.62 | 2022-2023 | Orladeyo |
| Kaleo, INC. | $21.19 | 2021 | |
| Horizon Therapeutics Plc | $19.75 | 2022 | |
| Optinose US, INC. | $19.14 | 2021 | |
| Incyte Corporation | $15.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorane Thornton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.